Shippeo Launches Second Edition of Visibility Now!, the Premier Event for Supply Chain & Transportation Visibility
10.11.2021 11:15:00 EET | Business Wire | Press release
Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the second edition of its customer community event Visibility Now! in partnership with Savoye, TESISQUARE®, and Siemens Digital Logistics. The hybrid event will take place both online and in-person in Paris on November 17 and offer a unique experience for all participants no matter where they are. From keynotes to customer testimonials and workshops and expert sessions, participants will have the chance to discover product insights and benefit from the expert’s points of view.
With covid border restrictions, container and driver shortages as well as the recent Suez Canal obstruction, now is the time for organizations to build resilient supply chains and visibility as a key enabler.
The event will include speakers from leading international organizations who will share their experiences on working with visibility solutions, outlining the critical roles they play in their digital transformation initiatives, and covering topics such as supply chain automation, global supply chain management, customer-centric approach and product innovation. Participants will have the opportunity to:
- Hear industry leaders discuss their experiences and best practices, including speakers from Renault Group, Coca-Cola HBC, DHL Freight, Nexans, Leroy Merlin, Philip Morris International, and Magnus Logistics
- Listen to top experts covering the latest trends, innovations, and guidelines to ensure transportation visibility project success such as Dr. John Gattorna, Siemens Digital Logistics, Savoye and TESISQUARE®
- Enjoy complimentary access to exclusive recorded sessions to dive deeper into trending topics on supply chain management and visibility
- Meet and engage with Shippeo’s team, alongside other Shippeo users and industry peers throughout the day
Global Supply Chain thought leader, Dr. John Gattorna, will share insights on designing future supply chains with embedded resilience, the challenges of operating global supply chain networks, and embracing multi-modal transportation as an integral part of future supply chains. He will also touch on the future role of 3PLs and 4PLs as genuine partners in the extended supply chain.
The event will include a live 90-minute plenary live show, broadcast from Paris in a dynamic and interactive format where participants will discover the latest insights, trends, and innovations related to supply chain and transportation visibility across a number of industry sectors. Several workshops and expert sessions will be held on demand for a deep dive into trending topics and best practices. These interactive workshops will provide an opportunity for participants to interact with other market leaders facing similar challenges and hear more about the latest news, insights, and product innovations in supply chain and transportation visibility from Shippeo experts.
“In the midst of supply chain disruptions, businesses have come to realize the value of real-time visibility and the need to take action, and further engage in digital transformation processes. We’re delighted to showcase the must-attend transportation visibility event and offer participants a place where they can hear from top industry experts, interact with other shippers, carriers, and logistics service providers from across the ecosystem to share and discover new ways to leverage visibility,” says Lucien Besse, COO of Shippeo.
The live show will stream from 1.30 pm on Wednesday 17th November. More information about the agenda, speakers, and how to register for the free event is available at shippeo.com/visibilitynow
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 850+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 25 million shipments per year across 74 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005610/en/
Contact information
Audrey Emanuel, audrey.emanuel@shippeo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom